The FDA has not said when it will decide, and the meeting gave no indication of a timeline. An NCI official warned that such tests could cause harm by creating a false sense of security. The evidence is mixed. The PATHFINDER 2 trial, published in Nature Medicine in September 2026, reported a 6.5-fold rise in detection when the test is used alongside routine screening. A separate analysis found a positive predictive value of 60.3% and specificity of 99.64% in people 50 and older with no clinical suspicion of cancer, but overall sensitivity of 39.3%. Independent reporting found the test missed more than two-thirds of cancers across all stages, and nearly 80% of early-stage cases over three annual screens. The NHS-Galleri trial has also raised doubts about broad multi-cancer detection. Medicare coverage depends on FDA approval, because Congress authorized coverage only for multi-cancer tests the agency has cleared.
Clinics are already offering Galleri, and marketing has run ahead of approval, including a Hims & Hers Super Bowl advertisement in February 2026. On November 10, 2026, a Nebraska health system said its cancer centers would offer the test starting November 2 for adults with elevated cancer risk. Attorneys advising health systems, telehealth companies, or patients should watch the FDA's decision and its final labeling conditions, especially limits on "early detection" claims. Any approval will also determine Medicare reimbursement. Exact Sciences' Cancerguard is marketed as a competing product but is not FDA cleared or approved, so claims about it carry separate regulatory risk.